Last updated 24 days ago
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
290 patients around the world
Available in Brazil, Mexico
Eli Lilly and Company
7Research sites
290Patients around the world
This study is for people with
Crohn's disease
Obesity
Requirements for the patient
To 70 Years
All Gender
Medical requirements
- Have had a diagnosis of Crohn's disease (CD) or perianal fistulizing CD established at least 3 months prior to enrollment confirmed by clinical, endoscopic, and histological criteria.Have obesity body mass index 30 kilograms per meter squared (BMI ≥30 kg/m2), or overweight (BMI ≥27 kg/m2 to <30 kg/m2) and in the presence of at least 1 of these weight-related comorbid conditions.Hypertension.Type 2 diabetes mellitus (T2DM).Dyslipidemia.Obstructive sleep apnea.Cardiovascular disease.Have moderately to severely active CD defined by a CDAI score of at least 220 at baseline.Have a centrally read Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥6 for patients with ileal-colonic or ≥4 for patients with isolated ileal disease within 21 days before the first dose of study treatment.Have a history of CD involving only or predominantly the colon for greater than or equal to 8 years with a surveillance colonoscopy within 1 year prior to baseline must have documented negative results for colorectal dysplasia and cancer.Have an inadequate response to, loss of response to, or intolerance to at least one conventional therapy.At least one conventional therapy (such as corticosteroids, oral azathioprine (AZA) or 60-mercaptopurine (6-MP), or oral aminosalicylates (for example, mesalamine, sulfasalazine, olsalazine, balsalazide)).At least one advanced therapy for CD (defined as: a biologic or biosimilar medication such as anti-tumor necrosis factor (TNF) antibodies, anti-integrin antibodies, Janus kinase (JAK) inhibitors such as upadacitinib, or anti-interleukin (IL)-12p40 antibodies, for example, ustekinumab).
- Have a current diagnosis of Ulcerative Colitis (UC), inflammatory bowel disease-unclassified (formerly known as indeterminate colitis), or primary sclerosing cholangitis.Have more than 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, left colon, and rectum.Currently have or are suspected to have an abscess.Have a stoma, ileoanal pouch, or ostomy.Have a history of more than 3 small bowel resections, diagnosis of short bowel syndrome, or any intestinal or non-intestinal intra-abdominal surgery within 3 months of baseline.Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening.Have had more than 5% body weight change in the past 3 months.Have a current or recent acute, active infection.
Sites
Fundação Universidade de Caxias do Sul
Clínica Hepatogastro JK
Cedoes - Pesquisa e Diagnóstico
CPQuali Pesquisa Clínica
Clínica Loema
Boca Clinical Trials Mexico SC - CDMX
Centro de Investigación Clínica Chapultepec - Sanatorio La Luz
StudyCOMMIT-CD
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Crohn's diseaseObesity
Requirements
To 70 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06937099
